[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Rajesh Narendran\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":87},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,65],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100440166","early-phase-1-c-11npa-pet-amphetamine-in-cocaine-use-disorders-100440166",false,"NCT05011760","[C-11]NPA PET-amphetamine in Cocaine Use Disorders","[C-11]NPA PET-amphetamine in Cocaine Use Disorders (Aim 2)","Inclusion Criteria:\n\n1. Males or females between 18 and 55 years old\n2. Fulfil DSM-5 criteria for cocaine use disorder\n3. No other current DSM-5 psychiatric or addictive disorders (such as major depressive disorder, bipolar disorders, psychotic disorders, etc.,)\n4. No current abuse (six months) of opiates, sedative-hypnotics, amphetamines, and MDMA as well as moderate to severe alcohol or cannabis use (twice a week). Nicotine use will be quantified and controlled between groups using the Fagerstrom Test for Nicotine Dependence (Heatherton et al., 1991);\n5. Not currently on prescription medical or psychotropic medications\n6. No current or past severe medical, endocrine or neurological illnesses including glaucoma, seizure disorders, hypertension, hypercholesterolemia as assessed by a complete medical history and physical\n7. Not currently pregnant or breastfeeding\n8. No history of significant radioactivity exposure in past year from another research study or occupation that exceeds RDRC guidelines\n9. No metallic objects in the body that are contraindicated for MRI\n10. No baseline BP ≥ 140\u002F90 and\u002For HR ≥ 100.\n11. No first-degree relative with an MI or stroke prior to middle age\n12. No first-degree relative with psychosis or mania.\n13. Completed a baseline \\[11C\\]NOP-1A PET scan in Aim 1 (Study Record: Imaging CRF X NOP interactions in Cocaine Use Disorders)","ALL","18 Years","55 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","This study uses \\[11C\\]NPA positron emission tomography (PET) and a d-amphetamine challenge to image amphetamine induced dopamine release in the striatum in subjects with cocaine use disorders (CUD). Amphetamine-induced dopamine release data from this study will be correlated with \\[11C\\]NOP-1A VT measured at baseline in the midbrain. \\[11C\\]NOP-1A PET data will be used from aim 1 (see, Study Record: Imaging CRF X NOP interactions in Cocaine Use Disorders)",[27],"Cocaine Use Disorder",[29],"[C-11]NOP-1A, [C-11]NPA , nociceptive opioid peptide receptors, dopamine release","RECRUITING","2026-06-06",{"date":33,"type":34},"2026-06-09","ACTUAL",{"date":36,"type":34},"2021-01-31",{"date":38,"type":21},"2028-09-01",{"name":40,"class":41},"Rajesh Narendran","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":64,"locationsCount":42},"100439888","early-phase-1-imaging-crf-x-nop-interactions-in-cud-100439888","NCT05008146","Imaging CRF X NOP Interactions in CUD","Imaging Corticotrophin-releasing Factor (CRF) X Nociceptive Opioid Peptide (NOP) Interactions in Cocaine Use Disorders (Aim 1)","Cocaine use disorders (CUD)\n\n1. Males or females between 18 and 55 years old\n2. Fulfil DSM-5 criteria for cocaine use disorder\n3. No other current DSM-5 psychiatric or addictive disorders (such as major depressive disorder, bipolar disorders, psychotic disorders, etc.,)\n4. No current abuse (six months) of opiates, sedative-hypnotics, amphetamines, MDMA, etc., as well as moderate to severe alcohol or cannabis use (twice a week). Nicotine use will be quantified and controlled between groups using the Fagerstrom Test for Nicotine Dependence (Heatherton et al., 1991);\n5. Not currently on prescription medical or psychotropic medications\n6. No current or past severe medical, endocrine or neurological illnesses including glaucoma, seizure disorders, hypertension, hypercholesterolemia as assessed by a complete medical history and physical\n7. Not currently pregnant or breastfeeding\n8. No history of significant radioactivity exposure in past year from another research study or occupation that exceeds RDRC guidelines\n9. No metallic objects in the body that are contraindicated for MRI\n\nHealthy Controls (HC)\n\n1. Males or females between 18 and 55 years old\n2. No present or past DSM-5 disorders (other than nicotine dependence)\n3. Criteria 5 to 9 as listed previously.",true,{"count":52,"type":21},80,[24],"This study uses \\[11C\\]NOP-1A positron emission tomography (PET) and a hydrocortisone challenge to image the interaction between nociceptive opioid peptide (NOP) receptors and cortisol\u002Fcorticotrophin releasing factor (CRF) in subjects with cocaine use disorders (CUD) and matched healthy controls (HC). It will also examine whether alterations in CRF x NOP interactions predict relapse in subjects with CUD.",[27],[57,58,59],"Cocaine use disorder","[C-11]NOP-1A PET","Nociceptive opioid peptide receptors",{"date":33,"type":34},{"date":62,"type":34},"2020-12-31",{"date":38,"type":21},{"name":40,"class":41},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":74,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":84,"leadSponsor":86,"locationsCount":42},"100638292","early-phase-1-imaging-crf-x-nop-interactions-in-alcohol-use-disorder-100638292","NCT07612631","Imaging CRF X NOP Interactions in Alcohol Use Disorder","Does a Hyperactive Nociceptin Opioid Peptide Receptor System Promote Relapse in Heavy Drinking AUD Subjects: a [C-11]NOP-1A and Hydrocortisone PET Study","Heavy drinking alcohol use disorder subjects (AUD)\n\n1. Males or females between 18 and 55 years old\n2. fulfill DSM-5 criteria for moderate or severe ( \\> or = 4 criteria) alcohol use disorder\n3. fulfill both NIAAA heavy drinking91 (consuming for males \\> or = 5 drinks on any day; for females \\> or = 4 drinks on any day) and WHO high-risk\u002Fvery high-risk drinking level criteria66 (for males \\> or = 30 drinks\u002Fweek; for females \\> or = 20 drinks\u002Fweek) in the past four weeks prior to enrollment\n4. No lifetime DSM-5 psychiatric disorders, including schizophrenia, schizoaffective disorder, bipolar disorder, or developmental disorders.\n5. No comorbid current DSM-5 depressive or anxiety disorders\n6. No other current DSM-5 substance use disorders, including opioids, cocaine, amphetamines, sedative-hypnotics, hallucinogens, and inhalants. Subjects with current moderate and severe DSM-5 cannabis use disorder will also be excluded\n7. Not currently on psychotropic medications that can directly (e.g., buprenorphine) or indirectly influence binding to NOP (e.g., medications that alter dopamine, GABA, glutamate, etc.) or modify alcohol consumption patterns (e.g., naltrexone, acamprosate, disulfiram);\n8. No regular use of medical medications that can potentially interact with hydrocortisone (other corticosteroids, mifepristone, etc.) or increase the risks associated with arterial line removal (warfarin, clopidogrel, aspirin, naproxen, ibuprofen, etc.)\n9. No clinically significant medical or neurological illnesses, including a history of immune compromise, HPA-axis dysfunction, Cushing's syndrome, glaucoma, morbid obesity, severe hyperglycemia, and hyperlipidemia, all of which are contraindications for hydrocortisone\n10. No history of anemia or history of deep vein thrombosis, pulmonary embolism, thrombocytopenia or thrombocytosis\n11. Not currently pregnant or breast-feeding\n12. No history of complicated alcohol withdrawal symptoms such as seizures, alcoholic hallucinosis, delirium tremens, or required admission to an inpatient detox program to prevent such symptoms\n13. Not currently employed as a radiation worker or has participated in a radiation-related research protocol within the previous year such that the total cumulative annual radiation dose (i.e., from participation in previous radioactive drug studies and this study) would exceed the radiation dose limits specified in the FDA regulations (i.e., 21 CFR 361.1) that govern the research use of radiotracers\n14. No metallic objects in the body that are contraindicated for MRI.\n\nHealthy Control subjects (HC)\n\n1. Males or females between 18 and 55 years old\n2. No DSM-5 psychiatric or substance use disorders other than tobacco use disorder\n3. No NIAAA heavy drinking in the past year (\\> or = 5 drinks on any day or more than 14 drinks per week for males; \\> or = 4 drinks on any day or more than 7 drinks per week for females)\n4. 7 to 14 above.",{"count":73,"type":21},90,[24],"This positron emission tomography imaging study uses \\[C-11\\]NOP-1A and hydrocortisone to image stress-modulating proteins in heavy drinking alcohol use disorder (AUD) subjects and healthy controls (HC). It will also characterize the role of these stress-regulating proteins in a relapse to alcohol.",[77],"Alcohol Use Disorder",[58,79],"Nociceptive opioid peptide receptor","2026-06-01",{"date":82,"type":34},"2026-06-03",{"date":80,"type":34},{"date":85,"type":21},"2032-06-30",{"name":40,"class":41},""]